Andere talen Immunotech Biopharm Ltd

Aandelen

6978

KYG4721A1004

Beurs gesloten - Hong Kong S.E. Andere beurzen 10:09:00 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
3,43 ^HKD	+0,88%		+3,63%	-31,40%

29/03	Immunotech Biopharm boekt bijna 335 miljoen yuan verlies in 2023	MT
28/03	Immunotech Biopharm Ltd rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Immunotech Biopharm Posts Nearly 335 Million Yuan Loss in 2023	29/03
Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Immunotech Biopharm Obtains Clinical Trial Nod in China for Leukemia Drug	19/02
Immunotech Biopharm Receives an Approval of the Investigational New Drug Application for Phase I Clinical Trial from the Centre for Drug Evaluation of the National Medical Products Administration for the aT19 Injection	19/02
Immunotech Biopharm Ltd Announces First Patient Enrolled in the Phase II Clinical Trialfor Car-T-19 Injection	03/01
Chinese Drug Regulator Accepts Immunotech Biopharm's Application for AT19 Injection	27/11
Immunotech Biopharm Enrolls First Patient in Clinical Trial of Lymphoma Drug	07/11
Immunotech Biopharm Ltd Completes the First Patient Enrolment for its Phase I Clinical Trial for the Denocabtagene Ciloleucel Injection	07/11
China Grants Breakthrough Therapy Designation to Immunotech's Liver Cancer Medication; Shares Fall 5%	06-09-23
Immunotech Biopharm Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	27-08-23
Immunotech Biopharm Ltd Announces Board Changes	27-08-23
Immunotech Biopharm Ltd Announces Director Changes	26-03-23
Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	24-03-23
Immunotech Biopharm Obtains China Clinical Trial Approval for Lymphoma Treatment	22-03-23
Immunotech Biopharm Ltd Obtains the Clinical Approval for the Denocabtagene Ciloleucel Injection from the National Medical Products Administration	21-03-23
Immunotech Biopharm Extends Completion Date of Convertible Bond Sale	26-01-23
Immunotech Biopharm’s New Drug Application for Lymphoma Injection Accepted by Chinese Regulator	29-12-22
Immunotech Biopharm Ltd. Receives Acceptance Notice for the Investigational New Drug Application for the Denocabtagene Ciloleucel Injection	28-12-22
Immunotech Biopharm Shareholders to Meet on Convertible Bond Issuance	16-12-22
Immunotech Biopharm Ltd announced that it expects to receive CNY 300 million in funding from Tianjin Tasly Pharmaceutical Co., Ltd., Investment Arm	28-10-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Immunotech Biopharm Ltd

Aandelen

6978

KYG4721A1004

Andere talen

Filters